Serves as the physician within oncology clinical programme teams, leading medical monitoring and safety oversight for lung and head/neck cancer studies. Interprets clinical and safety data, contributes to protocol development, and engages investigators, regulators and cross-functional matrix teams across Phase I–III development.
Serves as the physician within an oncology clinical program team, leading medical monitoring and safety oversight for genitourinary cancer studies. Interprets clinical and safety data, contributes to protocol development and regulatory interactions, and acts as a core member of the Clinical Matrix Team. Hybrid role requiring on-site presence at least two days per week.
Leads the design and execution of clinical biomarker and translational medicine strategies for late-stage oncology assets, defining patient segmentation and decision criteria within Clinical Matrix Teams. Oversees biomarker assay development, sample testing plans and data packages across platforms such as NGS, IHC, flow cytometry and ctDNA, working with internal and external partners.
Leads the design and execution of clinical biomarker and translational medicine strategies for late-stage oncology assets, defining patient segmentation and decision criteria within Clinical Matrix Teams. Validates predictive, pharmacodynamic and resistance biomarkers using platforms such as NGS, ctDNA, flow cytometry and multi-omic analyses to inform dose selection and go/no-go decisions.
Leads the design and execution of clinical biomarker and translational medicine strategies for late-stage oncology assets, defining patient segmentation and decision criteria within Clinical Matrix Teams. Oversees biomarker assay development, sample testing plans and data packages across platforms such as NGS, IHC, flow cytometry and ctDNA, working with internal and external partners.
Manages statistical planning and delivery across oncology clinical programs, designing trials and analyses that shape development decisions and regulatory strategy. Works with clinical, regulatory, safety and clinical pharmacology teams, using simulation and advanced methods such as Bayesian and adaptive designs, while mentoring statisticians.
Manages statistical planning and delivery across oncology clinical programs, designing trials and analyses that shape development decisions and regulatory strategy. Works with clinical, regulatory, safety and clinical pharmacology teams, using simulation and advanced methods in R or Python, and mentors statisticians. Based in London or Stevenage, with a planned relocation to Cambridge by early 2029.
Leads the scientific design and execution of interventional clinical studies within Medical Affairs, providing medical governance, safety data review and scientific oversight of protocols and analysis plans. Collaborates with cross-functional teams, investigators and thought leaders, and presents results for publications and regulatory submissions. Hybrid role with two to three days per week in office.
Leads the scientific design and execution of interventional clinical studies within Medical Affairs, providing medical governance, safety data review and scientific oversight of protocols and analysis plans. Collaborates with cross-functional teams, investigators and thought leaders, and presents results for publications and regulatory submissions. Hybrid role with two to three days per week in office.
Leads the scientific design and execution of interventional clinical studies within Medical Affairs, providing medical governance, safety oversight and scientific interpretation of protocols and analysis plans. Collaborates with cross-functional teams, investigators and regulators, and presents results for publications and submissions. Hybrid role with two to three days per week in office.
Leads end-to-end clinical development of hematology oncology assets from first-in-human studies through registrational trials, regulatory approval and launch. Sets disease-area strategy, chairs governance forums and scientific advisory boards, and line-manages clinical development leads and medical directors within a global matrix team.
Leads end-to-end clinical development of hematology oncology assets from first-in-human studies through registrational trials, regulatory approval and launch. Provides portfolio oversight, chairs governance forums and scientific advisory boards, and line-manages Clinical Development Leads and Medical Directors within a global matrix team.
Leads end-to-end clinical development strategy for a hematology oncology portfolio, from first-in-human studies through registrational trials, regulatory approval and initial launch. Provides program oversight at governance forums, co-leads asset development with matrix partners, and line-manages Clinical Development Leads, Medical Directors and Clinical Scientists. Champions novel approaches such as AI/ML, innovative trial designs and real-world data.
Leads end-to-end clinical development of hematology oncology assets from first-in-human studies through registrational trials, approval and launch. Sets disease-area strategy, chairs governance forums and advisory boards, and line-manages clinical development leads within a global matrix. Distinct for its portfolio-level enterprise scope and hybrid US/UK/Swiss base.
Leads end-to-end clinical development of hematology oncology assets from first-in-human studies through registrational trials, regulatory approval and initial launch. Chairs governance forums, co-leads matrix asset teams and line-manages clinical development leads, medical directors and clinical scientists. Distinct for its portfolio-level scope across early- and late-phase programs and its cross-functional connector role spanning research, translational medicine and commercial strategy.
